DUBLIN, June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 RELEASE MSS1 trial (NCT04657666) evaluating nabiximols oromucosal spray ...

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) said Tuesday that phase 3 RELEASE MSS1 trial, which evaluated nabiximols oromucosal spray on clinical measures of spasticity in individuals with multiple ...

If you are one of the 2.5 million people worldwide living with multiple sclerosis, you likely already know some of the challenges of staying active with the condition. Hearing the words “you have MS” ...

Spasticity is a condition that affects your muscles, making them tight or stiff. This can impact your ability to perform daily activities, such as walking, eating, and talking. The condition may also ...